Protein misfolding cyclic amplification

Last updated

Protein misfolding cyclic amplification (PMCA) is an amplification technique (conceptually like polymerase chain reaction (PCR) but not involving nucleotides) to multiply misfolded prions originally developed by Soto and colleagues. [1] It is a test for spongiform encephalopathies like chronic wasting disease (CWD) [2] or bovine spongiform encephalopathy (BSE).

Contents

Technique

The technique initially incubates a small amount of abnormal prion with an excess of normal protein, so that some conversion takes place. The growing chain of misfolded protein is then blasted with ultrasound, breaking it down into smaller chains and so rapidly increasing the amount of abnormal protein available to cause conversions. [1] [3] By repeating the cycle, the mass of normal protein is rapidly changed into the prion being tested for.[ citation needed ]

Development

PMCA was originally developed to, in vitro, mimic prion replication with a similar efficiency to the in vivo process, but with accelerated kinetics. [1] PMCA is conceptually analogous to the polymerase chain reaction - in both systems a template grows at the expense of a substrate in a cyclic reaction, combining growing and multiplication of the template units.[ citation needed ]

Replication

PMCA has been applied to replicate the misfolded protein from diverse species. [4] [5] [6] The newly generated protein exhibits the same biochemical, biological, and structural properties as brain-derived PrPSc and strikingly it is infectious to wild type animals, producing a disease with similar characteristics as the illness produced by brain-isolated prions. [7]

Automation

The technology has been automated, leading to a dramatic increase in the efficiency of amplification. Now, a single cycle results in a 2500-fold increase in sensitivity of detection over western blotting, [8] whereas 2 and 7 consecutive cycles result in 6 million and 3 billion-fold increases in sensitivity of detection over western blotting, a technique widely used in BSE surveillance in several countries. [8]

Sensitivity

It has been shown that PMCA is capable of detecting as little as a single molecule of oligomeric infectious PrPSc. [8] PMCA possesses the ability to generate millions infectious units, starting with the equivalent to one PrPSc oligomer; well below the infectivity threshold. [8] This data demonstrates that PMCA has a similar power of amplification as PCR techniques used to amplify DNA. It opens a great promise for development of a highly sensitive detection of PrPSc, and for understanding the molecular basis of prion replication. Indeed, PMCA has been used by various groups to PrPSc in blood of animals experimentally infected with prions during both the symptomatic [9] and pre-symptomatic phases [10] as well as in urine. [11]

Uses

The PMCA technology has been used by several groups to understand the molecular mechanism of prion replication, the nature of the infectious agent, the phenomenon of prion strains and species barrier, the effect of cellular components, to detect PrPSc in tissues and biological fluids and to screen for inhibitors against prion replication. [12] [13] [14] Recent studies by the groups of Supattapone and Ma were able to produce prion replication in vitro by PMCA using purified PrPC and recombinant PrPC with the sole addition of synthetic polyanions and lipids. [15] [16] These studies have shown that infectious prions can be produced in the absence of any other cellular component and constitute some of the strongest evidence in favor of the prion hypothesis.

Research in 2020 concluded that protein misfolding cyclic amplification could be used to distinguish between two progressive neurodegenerative diseases, Parkinson's disease and multiple system atrophy, being the first process to give an objective diagnosis of Multiple System Atrophy instead of just a differential diagnosis. [17] [18]

See also

Related Research Articles

<span class="mw-page-title-main">Creutzfeldt–Jakob disease</span> Degenerative neurological disorder

Creutzfeldt–Jakob disease (CJD), also known as subacute spongiform encephalopathy or neurocognitive disorder due to prion disease, is a fatal degenerative brain disorder. Early symptoms include memory problems, behavioral changes, poor coordination, and visual disturbances. Later symptoms include dementia, involuntary movements, blindness, weakness, and coma. About 70% of people die within a year of diagnosis. The name Creutzfeldt–Jakob disease was introduced by Walther Spielmeyer in 1922, after the German neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob.

<span class="mw-page-title-main">Prion</span> Pathogenic type of misfolded protein

A prion is a misfolded protein that can induce misfolding of normal variants of the same protein and trigger cellular death. Prions cause prion diseases known as transmissible spongiform encephalopathies (TSEs) that are transmissible, fatal neurodegenerative diseases in humans and animals. The proteins may misfold sporadically, due to genetic mutations, or by exposure to an already misfolded protein. The consequent abnormal three-dimensional structure confers on them the ability to cause misfolding of other proteins.

<span class="mw-page-title-main">Stanley B. Prusiner</span> American neurologist and biochemist

Stanley Ben Prusiner is an American neurologist and biochemist. He is the director of the Institute for Neurodegenerative Diseases at University of California, San Francisco (UCSF). Prusiner discovered prions, a class of infectious self-reproducing pathogens primarily or solely composed of protein, considered by many as a heretical idea when first proposed. He received the Albert Lasker Award for Basic Medical Research in 1994 and the Nobel Prize in Physiology or Medicine in 1997 for prion research developed by him and his team of experts beginning in the early 1970s.

<span class="mw-page-title-main">Scrapie</span> Degenerative disease that affects sheep and goats

Scrapie is a fatal, degenerative disease affecting the nervous systems of sheep and goats. It is one of several transmissible spongiform encephalopathies (TSEs), and as such it is thought to be caused by a prion. Scrapie has been known since at least 1732 and does not appear to be transmissible to humans. However, it has been found to be experimentally transmissible to humanised transgenic mice and non-human primates.

<span class="mw-page-title-main">Transmissible spongiform encephalopathy</span> Group of brain diseases induced by prions

Transmissible spongiform encephalopathies (TSEs) also known as prion diseases, are a group of progressive, incurable, and fatal conditions that are associated with prions and affect the brain and nervous system of many animals, including humans, cattle, and sheep. According to the most widespread hypothesis, they are transmitted by prions, though some other data suggest an involvement of a Spiroplasma infection. Mental and physical abilities deteriorate and many tiny holes appear in the cortex causing it to appear like a sponge when brain tissue obtained at autopsy is examined under a microscope. The disorders cause impairment of brain function, including memory changes, personality changes and problems with movement that worsen chronically.

<span class="mw-page-title-main">Chronic wasting disease</span> Prion disease affecting the deer family

Chronic wasting disease (CWD), sometimes called zombie deer disease, is a transmissible spongiform encephalopathy (TSE) affecting deer. TSEs are a family of diseases thought to be caused by misfolded proteins called prions and include similar diseases such as BSE in cattle, Creutzfeldt–Jakob disease (CJD) in humans and scrapie in sheep. Natural infection causing CWD affects members of the deer family. In the United States, CWD affects mule deer, white-tailed deer, red deer, sika deer, elk, caribou, and moose. Experimental transmission of CWD to other species such as squirrel monkeys and genetically modified mice has been shown.

<span class="mw-page-title-main">Amyloid</span> Insoluble protein aggregate with a fibrillar morphology

Amyloids are aggregates of proteins characterised by a fibrillar morphology of typically 7–13 nm in diameter, a β-sheet secondary structure and ability to be stained by particular dyes, such as Congo red. In the human body, amyloids have been linked to the development of various diseases. Pathogenic amyloids form when previously healthy proteins lose their normal structure and physiological functions (misfolding) and form fibrous deposits within and around cells. These protein misfolding and deposition processes disrupt the healthy function of tissues and organs.

<span class="mw-page-title-main">Major prion protein</span> Protein involved in multiple prion diseases

Major prion protein (PrP) is encoded in the human body by the PRNP gene also known as CD230. Expression of the protein is most predominant in the nervous system but occurs in many other tissues throughout the body.

Laura Manuelidis is a physician and neuropathologist at Yale University.

<span class="mw-page-title-main">Proteinopathy</span> Medical condition

In medicine, proteinopathy, or proteopathy, protein conformational disorder, or protein misfolding disease, is a class of diseases in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body. Often the proteins fail to fold into their normal configuration; in this misfolded state, the proteins can become toxic in some way or they can lose their normal function. The proteinopathies include such diseases as Creutzfeldt–Jakob disease and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, and a wide range of other disorders. The term proteopathy was first proposed in 2000 by Lary Walker and Harry LeVine.

<span class="mw-page-title-main">Kuru (disease)</span> Rare neurodegenerative disease caused by prions

Kuru is a rare, incurable, and fatal neurodegenerative disorder that was formerly common among the Fore people of Papua New Guinea. Kuru is a form of transmissible spongiform encephalopathy (TSE) caused by the transmission of abnormally folded proteins (prions), which leads to symptoms such as tremors and loss of coordination from neurodegeneration.

<span class="mw-page-title-main">Protein aggregation</span> Accumulation of clumps of misfolded or disordered proteins

In molecular biology, protein aggregation is a phenomenon in which intrinsically-disordered or mis-folded proteins aggregate either intra- or extracellularly. Protein aggregates have been implicated in a wide variety of diseases known as amyloidoses, including ALS, Alzheimer's, Parkinson's and prion disease.

<span class="mw-page-title-main">Bovine spongiform encephalopathy</span> Fatal neurodegenerative disease of cattle

Bovine spongiform encephalopathy (BSE), commonly known as mad cow disease, is an incurable and invariably fatal neurodegenerative disease of cattle. Symptoms include abnormal behavior, trouble walking, and weight loss. Later in the course of the disease the cow becomes unable to function normally. There is conflicting information about the time between infection and onset of symptoms. In 2002, the World Health Organization (WHO) suggested it to be approximately four to five years. Time from onset of symptoms to death is generally weeks to months. Spread to humans is believed to result in variant Creutzfeldt–Jakob disease (vCJD). As of 2018, a total of 231 cases of vCJD had been reported globally.

<span class="mw-page-title-main">Surround optical-fiber immunoassay</span>

Surround optical-fiber immunoassay (SOFIA) is an ultrasensitive, in vitro diagnostic platform incorporating a surround optical-fiber assembly that captures fluorescence emissions from an entire sample. The technology's defining characteristics are its extremely high limit of detection, sensitivity, and dynamic range. SOFIA's sensitivity is measured at the attogram level (10−18 g), making it about one billion times more sensitive than conventional diagnostic techniques. Based on its enhanced dynamic range, SOFIA is able to discriminate levels of analyte in a sample over 10 orders of magnitude, facilitating accurate titering.

<span class="mw-page-title-main">JUNQ and IPOD</span> Types of cytosolic protein inclusion bodies

JUNQ and IPOD are types of cytosolic protein inclusion bodies in eukaryotes.

Frank O. Bastian is an American medical doctor and neuropathologist, who previously worked at Louisiana State University, moved to a university in New Orleans in 2019. He specializes in the transmissible spongiform encephalopathies (TSEs), which include, but are not limited to, Bovine spongiform encephalopathy (BSE) "Mad cow disease" in cattle, scrapie in sheep and goats, and Creutzfeldt–Jakob disease (CJD) in humans.

Diseases of abnormal polymerization, or simply DAPs, are a class of disorders characterized by a novel alteration in base unit proteins that results in a structure with pathogenic potential. This functional alteration in a protein in relation to its thermodynamic and kinetic properties enacts an extended chain response among neighboring proteins until an extensive and potentially harmful polymerized structure is formed. Due to this endogenous foreign formation, these diseases are often untreatable and very severe in clinical manifestation. Although DAPs are rare infections, the poor outcome in patients and the need for further understanding makes this class of diseases a pillar for future research.

<span class="mw-page-title-main">United Kingdom BSE outbreak</span> Mad cow disease outbreak in the 1980s and 90s

The United Kingdom was afflicted with an outbreak of Bovine spongiform encephalopathy, and its human equivalent variant Creutzfeldt–Jakob disease (vCJD), in the 1980s and 1990s. Over four million head of cattle were slaughtered in an effort to contain the outbreak, and 178 people died after contracting vCJD through eating infected beef. A political and public health crisis resulted, and British beef was banned from export to numerous countries around the world, with some bans remaining in place until as late as 2019.

Real-time quaking-induced conversion (RT-QuIC) is a highly sensitive assay for prion detection.

Michael Coulthart is a Canadian microbiologist who is employed as the head of the Canadian Creutzfeldt–Jakob Disease Surveillance System (CJDSS) within the Public Health Agency of Canada (PHAC), which terms CJD a zoonotic and infectious disease. In 2006, a working group named "classic CJD" as well as Variant Creutzfeldt–Jakob disease as two notifiable diseases. It is unknown whether PHAC tracks in an official capacity other transmissible spongiform encephalopathies (TSE), but Coulthart is on the Advisory Committee of the Center for Infectious Disease Research and Policy for Chronic Wasting Disease of cervidae.

References

  1. 1 2 3 Saborio, G.P., Permanne, B. and Soto, C. (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature, 411, 810-813.
  2. ↑ Patrice N Klein, CWD Program Manager USDA/APHIS. "Chronic Wasting Disease - APHIS Proposed Rule to Align BSE Import Regulations to OIE" (PDF). WHHCC Meeting – 5–6 February 2013. Archived from the original (PDF) on 26 September 2014.{{cite web}}: CS1 maint: location (link)
  3. ↑ Soto, C., Saborio, G.P. and Anderes, L. (2002) Cyclic amplification of protein misfolding: application to prion- related disorders and beyond. Trends Neurosci., 25, 390-394.
  4. ↑ Soto, C., Anderes, L., Suardi, S., Cardone, F., Castilla, J., Frossard, M.J., Peano, S., Saá, P., Limido, L., Carbonatto, M., Ironside, J., Torres, J.M., Pocchiari, M. and Tagliavini, F. (2005) Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. FEBS Lett., 579, 638-642.
  5. ↑ Jones, M., Peden, A.H., Prowse, C.V., Groner, A., Manson, J.C., Turner, M.L., Ironside, J.W., MacGregor, I.R. and Head, M.W. (2007) In vitro amplification and detection of variant Creutzfeldt–Jakob disease PrPSc. J.Pathol., 213, 21-26.
  6. ↑ Kurt, T.D., Perrott, M.R., Wilusz, C.J., Wilusz, J., Supattapone, S., Telling, G.C., Zabel, M.D. and Hoover, E.A. (2007) Efficient in vitro amplification of chronic wasting disease PrPRES. J.Virol., 81, 9605-9608.
  7. ↑ Castilla, J., Saá, P., Hetz, C. and Soto, C. (2005) In vitro generation of infectious scrapie prions. Cell, 121, 195-206.
  8. 1 2 3 4 Saa, P., Castilla, J. and Soto, C. (2006) Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J.Biol.Chem., 281, 35245-35252.
  9. ↑ Castilla, J., Saa, P. and Soto, C. (2005) Detection of prions in blood. Nat.Med., 11, 982-985.
  10. ↑ Saa, P., Castilla, J. and Soto, C. (2006) Presymptomatic detection of prions in blood. Science, 313, 92-94.
  11. ↑ Gonzalez-Romero, D., Barria, M.A., Leon, P., Morales, R. and Soto, C. (2008) Detection of infectious prions in urine. FEBS Lett., 582, 3161-3166.
  12. ↑ Castilla, J., Gonzalez-Romero, D., Saa, P., Morales, R., De, C.J. and Soto, C. (2008) Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell, 134, 757-768.
  13. ↑ Barria, M.A., Mukherjee, A., Gonzalez-Romero, D., Morales, R. and Soto, C. (2009) De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS.Pathog., 5, e1000421.
  14. ↑ Deleault, N.R., Lucassen, R.W. and Supattapone, S. (2003) RNA molecules stimulate prion protein conversion. Nature, 425, 717-720.
  15. ↑ Deleault, N.R., Harris, B.T., Rees, J.R. and Supattapone, S. (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 104, 9741-9746.
  16. ↑ Wang, F., Wang, X., Yuan, C.-G. and Ma, J. (2010) Generating a Prion with Bacterially Expressed Recombinant Prion Protein. Science 327, 1132-1135.
  17. ↑ "Method Can Distinguish Parkinson's Disease From multiple system atrophy". Diagnostics from Technology Networks. Retrieved 23 February 2020.
  18. ↑ Shahnawaz, Mohammad; Mukherjee, Abhisek; Pritzkow, Sandra; Mendez, Nicolas; Rabadia, Prakruti; Liu, Xiangan; Hu, Bo; Schmeichel, Ann; Singer, Wolfgang; Wu, Gang; Tsai, Ah-Lim; Shirani, Hamid; Nilsson, K. Peter R.; Low, Phillip A.; Soto, Claudio (5 February 2020). "Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy". Nature. 578 (7794): 273–277. Bibcode:2020Natur.578..273S. doi:10.1038/s41586-020-1984-7. PMC   7066875 . PMID   32025029.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.